Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 9, 2016, Pages 926-935

  Horvath, A ^a   Leber, B ^a,b   Schmerboeck, B ^a   Tawdrous, M ^a   Zettel, G ^a   Hartl, A ^a   Madl, T ^a   Stryeck, S ^a   Fuchs, D ^c   Lemesch, S ^a   Douschan, P ^a   Krones, E ^a   Spindelboeck, W ^a   Durchschein, F ^a   Rainer, F ^a   Zollner, G ^a   Stauber, R E ^a   Fickert, P ^a   Stiegler, P ^a   Stadlbauer, V ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Centre for Biomarker Research in Medicine (CBmed)   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; NEOPTERIN; PLACEBO; PROBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; HUMAN; INFECTION; INFLAMMATION; INNATE IMMUNITY; INTESTINE MUCOSA PERMEABILITY; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHIL; PATIENT COMPLIANCE; PHAGOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN;

EID: 84991080789     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13788     Document Type: Article

References (43)

1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448–57.
2. WHO. The global burden of disease. 2004 Update, 2008.
3. Shawcross DL, Wright GA, Stadlbauer V, et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008; 48: 1202–12.
4. Taylor NJ, Nishtala A, Manakkat Vijay GK, et al. Circulating neutrophil dysfunction in acute liver failure. Hepatology 2013; 57: 1142–52.
5. Tritto G, Bechlis Z, Stadlbauer V, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol 2011; 55: 574–81.
6. Nieto JC, Sanchez E, Romero C, et al. Impaired innate immune response of leukocytes from ascitic fluid of patients with spontaneous bacterial peritonitis. J Leukocyte Biol 2015; 98: 819–25.
7. Stadlbauer V, Mookerjee RP, Wright GA, et al. Role of toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G15–22.
8. Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46: 831–40.
9. Taylor NJ, Manakkat Vijay GK, Abeles RD, et al. The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther 2014; 40: 705–15.
10. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422–33.
11. Lamb FS, Hook JS, Hilkin BM, Huber JN, Volk AP, Moreland JG. Endotoxin priming of neutrophils requires endocytosis and NADPH oxidase-dependent endosomal reactive oxygen species. J Biol Chem 2012; 287: 12395–404.
12. Balmer ML, Slack E, deGottardi A, et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Science Transl Med 2014; 6: 237ra66.
13. Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol 2011; 45(Suppl.): S168–71.
14. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441–9.
15. Lata J, Novotny I, Pribramska V, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19: 1111–3.
16. Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014; 147: 1327–37.e3.
17. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675–82.
18. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945–51.
19. ® BARRIER on parameters of intestinal barrier function. Food Nutr Sci 2014; 5: 1739–45.
20. Razumovitch JA, Fuchs D, Semenkova GN, Cherenkevich SN. Influence of neopterin on generation of reactive species by myeloperoxidase in human neutrophils. Biochim Biophys Acta 2004; 1672: 46–50.
21. Zangenah S, Bergman P. Rapid killing of Capnocytophaga canimorsus and Capnocytophaga cynodegmi by human whole blood and serum is mediated via the complement system. SpringerPlus 2015; 4: 517.
22. Homann C, Varming K, Hogasen K, et al. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997; 40: 544–9.
23. Luthje P, Brauner A. Novel strategies in the prevention and treatment of urinary tract infections. Pathogens 2016; 5: doi: 10.3390/pathogens5010013.
24. Lamontagne A, Long RE, Comunale MA, et al. Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection. PLoS ONE 2013; 8: e64992.
25. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003; 52: 313–21.
26. Hamerlinck FFV. Neopterin: a review. Exp Dermatol 1999; 8: 167–76.
27. Leber B, Spindelboeck W, Stadlbauer V. Infectious complications of acute and chronic liver disease. Semin Respir Crit Care Med 2012; 33: 80–95.
28. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26–42.
29. Guerrero Hernandez I, Torre Delgadillo A, Vargas Vorackova F, Uribe M. Intestinal flora, probiotics, and cirrhosis. Ann Hepatol 2008; 7: 120–4.
30. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60: 1310–24.
31. Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation–a randomized, double-blind trial. Am J Transplant 2005; 5: 125–30.
32. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32–7.
33. Chen P, Torralba M, Tan J, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 2015; 148: 203–14 e16.
34. Lamprecht M, Bogner S, Schippinger G, et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr 2012; 9: 45.
35. Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003; 50: 1482–6.
36. Tripathi A, Lammers KM, Goldblum S, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 2009; 106: 16799–804.
37. Fukui H. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol 2015; 7: 425–42.
38. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540–3.
39. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651–9.
40. Stadlbauer V. Immunosuppression and probiotics: are they effective and safe? Beneficial Microbes 2015; 6: 823–8.
41. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189.
42. Stadlbauer V, Davies NA, Wright G, Jalan R. Endotoxin measures in patients' sample: how valid are the results? J Hepatol 2007; 47: 726–7; author reply 7-3.
43. Horvath A, Leber B, Schmerboeck B, Stadlbauer V. Endotoxinmessung bei Leberzirrhose: Ein Methodenvergleich. Z Gastroenterol 2015; 53: P92.